Archives: Speakers

Earl Tanmantiong has served as Director and Chief Technology Officer of HBNB since March 3, 2025. In addition, Mr. Tanmantiong has served as Chief Technology Officer of Hotel101 Global since 2024. Prior to joining Hotel101 Global, Mr. Tanmantiong served as Founder and President of Earl Hotel Revenue Management Corp., a revenue management service provider for hotel chains in the Philippines, from 2017 to 2024; and as Director of Revenue Management for Hilton-branded hotels in Manhattan, New York City, from 2013 to 2016. Mr. Tanmantiong holds a Bachelor of Science in Hotel Administration, Cum Laude, from Cornell University.

With over two decades of experience spanning consulting, business development, and sales management, Rana serves as the pioneering sales leader for the ASEAN market at ClickHouse. Originally from Australia and now a long-time resident of Singapore, he has spent the last 15 years specializing in business analytics and database technologies. Rana is passionate about delivering tailored, cutting-edge solutions that meet both the immediate and future needs of his clients. Throughout his career, Rana has held key roles at industry-leading companies, including Confluent, Hasura, IBM, and Tridant, among others. His expertise lies in helping organizations unlock the full potential of their data through innovative strategies and solutions.

My professional history is directly related to my 20+ years’ experience managing operations in healthcare sector across multiple locations, including Europe, US and Canada. What makes me stand-out is my record of optimising current processes to deliver quality services, establishing and growing businesses, and increasing staff performance and satisfaction. I am meticulous, creative, and focused professional with proven talent to foster productive relationships with top businesses / clients across all pharma segments. I excel at managing projects in all clinical phases, overseeing large budgets, as well as directing multidisciplinary global teams to exceed company KPIs while keeping the people development & care as main driver.

Stacy Lee is a Global Clinical Project Manager at Novotech. With a background in Human Biology and over 13 years of experience in global clinical operations, she has led multi-country oncology and radiopharmaceutical programs from early development through pivotal stages. Recognized as a subject matter expert in radiopharmaceutical clinical trials, Stacy specializes in translating complex science into operational strategy, proactive risk assessment, and mitigation planning to ensure trial integrity and delivery excellence. She is passionate about advancing targeted therapies and strengthening global partnerships to accelerate clinical development worldwide.

Dr. Hyojin Park earned his Bachelor’s degree in Psychology from Indiana University Bloomington and his Doctorate in Medical Sciences from Yonsei University. He is currently with GlobalData, where he leads consulting and data solution initiatives for the pharmaceutical and biotechnology sectors, supporting both industry and government clients. Prior to this, he served as a Senior Consultant at Clarivate, working on strategic projects across global life sciences markets. Since 2021, Dr. Park has presented data-driven analyses and market outlooks on the pharmaceutical and biotech industries at major conferences and government-sponsored events.

Guido Wuerth joined Affibody AB in September 2021, where he serves as Head of Corporate Development, Radiopharma. In this role, he oversees asset management across the company’s radiopharmaceutical portfolio.

He joined Affibody from MorphoSys, where he led Clinical Development and served as Global Program Head for several immunology programs. During his tenure, he played a key role in the U.S. approval of tafasitamab (MONJUVI®) for the treatment of Non-Hodgkin Lymphoma and contributed to the successful execution of multi-million Euro out-licensing agreements.

Prior to 2017, he managed Global Clinical Operations at Sandoz, leading a team of approximately 100 professionals. Earlier at Sandoz, he served as Global Program Medical Director for the clinical development of the etanercept biosimilar Erelzi®, gaining extensive experience in regulatory interactions with health authorities.

Previously, Guido held global roles in Clinical Development and Clinical Operations at Baxter BioSciences, Antisense Pharma, and Schwarz Pharma (now part of UCB). He is a board-certified urologist and holds a medical degree from the University of Cologne, Germany.